Pharma-Bio Serv (PBSV) Equity Average (2011 - 2026)

Pharma-Bio Serv's Equity Average history runs 14 years deep, the most recent figure standing at $10.3 million for Q2 2026.

• Equity Average for Q2 2026 came in at $10.3 million, down 14.21% year-over-year; the trailing twelve-month figure through Apr 2026 was $10.3 million (down 14.21% YoY), and the FY2025 annual result was $12.8 million, down 14.12% from the prior year.
• Equity Average came in at $10.3 million for Q2 2026 at Pharma-Bio Serv, down from $11.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $18.2 million in Q1 2022 to a low of $10.3 million in Q2 2026.
• A 5-year average of $14.4 million and a median of $14.6 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average fell 29.4% in 2022 and fell 0.57% in 2023, its largest moves.
• Over 5 years, Equity Average stood at $16.4 million in 2022, then fell by 1.2% to $16.2 million in 2023, then declined by 15.2% to $13.7 million in 2024, then dropped by 13.0% to $11.9 million in 2025, then decreased by 13.2% to $10.3 million in 2026.
• The last three Equity Average figures came in at $10.3 million (Q2 2026), $11.1 million (Q1 2026), and $11.9 million (Q4 2025), per Business Quant data.